Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial-Reference-Cited by-同舟云学术

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Published:2021-04 Issue:4 Volume:16 Page:653-664
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Nishio Makoto,Barlesi Fabrice,West Howard,Ball Simon,Bordoni Rodolfo,Cobo Manuel,Longeras Pascale Dubray,Goldschmidt Jerome,Novello Silvia,Orlandi Francisco,Sanborn Rachel E.,Szalai Zsuzsanna,Ursol Grigoriy,Mendus Diana,Wang Lijia,Wen Xiaohui,McCleland Mark,Hoang Tien,Phan See,Socinski Mark A.

Funder

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study;JAMA Oncol,2018

2. The evolving role of histology in the management of advanced non-small-cell lung cancer;Langer;J Clin Oncol,2010

3. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2019;30:863–870];Planchard;Ann Oncol,2018

4. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

5. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

Cited by 309 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature;Cancers;2024-09-08

2. Locoregional therapies combined with immune checkpoint inhibitors for liver metastases;Cancer Cell International;2024-08-31

3. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer;Journal of Clinical Oncology;2024-08-22

4. High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group);Japanese Journal of Clinical Oncology;2024-08-19

5. Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2024-08-13